Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,400 shares of the company’s stock after purchasing an additional 300 shares during the quarter. Catalyst Funds Management Pty Ltd’s holdings in Vaxcyte were worth $1,506,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its holdings in Vaxcyte by 23.1% during the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. raised its holdings in Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after purchasing an additional 485,436 shares in the last quarter. State Street Corp raised its holdings in Vaxcyte by 1.1% during the third quarter. State Street Corp now owns 3,405,743 shares of the company’s stock worth $389,174,000 after purchasing an additional 38,596 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after acquiring an additional 324,560 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Vaxcyte by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after acquiring an additional 259,010 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. The trade was a 6.81 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,250 shares of company stock worth $4,550,258. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $74.37 on Friday. The firm’s fifty day moving average price is $82.24 and its 200 day moving average price is $94.26. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06. The firm has a market cap of $9.58 billion, a price-to-earnings ratio of -16.17 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PCVX. Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday. The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.